Analyst Price Targets — TELA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 1, 2025 1:42 pm | Frank Takkinen | Loop Capital Markets | $3.00 | $1.17 | StreetInsider | TELA Bio, Inc. (TELA) PT Lowered to $3 at Lake Street Capital Markets |
| December 1, 2025 1:41 pm | — | Lake Street | $3.00 | $1.24 | TheFly | Tela Bio price target lowered to $3 from $6 at Lake Street |
| November 14, 2025 1:13 pm | — | Piper Sandler | $1.25 | $0.93 | StreetInsider | TELA Bio, Inc. (TELA) PT Lowered to $1.25 at Piper Sandler |
| October 4, 2024 8:46 am | Frank Takkinen | Lake Street | $8.00 | $2.52 | TheFly | Tela Bio's OviTex 'primary beneficiary' of BD settlement, says Lake Street |
| August 13, 2024 6:38 am | Matt O'Brien | Piper Sandler | $8.00 | $4.01 | TheFly | Tela Bio price target lowered to $8 from $10 at Piper Sandler |
| May 22, 2024 6:24 am | Kyle Rose | Canaccord Genuity | $14.00 | $6.20 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on TELA Bio, Inc. (TELA) |
| May 10, 2024 8:21 am | Matt O'Brien | Piper Sandler | $10.00 | $5.78 | StreetInsider | TELA Bio, Inc. (TELA) PT Lowered to $10 at Piper Sandler |
| November 10, 2022 9:57 am | — | JMP Securities | $20.00 | $8.10 | Benzinga | JMP Securities Maintains Market Outperform on TELA Bio, Lowers Price Target to $20 |
| November 9, 2022 9:09 pm | Matt O'Brien | Piper Sandler | $15.00 | $6.50 | TheFly | Tela Bio price target lowered to $15 from $20 at Piper Sandler |
Latest News for TELA
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.25 per share a year ago.
MALVERN, Pa. , May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Announced strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting on June 9, 2026; Noted the…
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026.
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 89,250 shares of its common stock to 12 newly-hired employees,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TELA.
U.S. House Trading
No House trades found for TELA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.